The move is aimed at improving Aptar’s support for the early-stage development of drugs by providing formulation, fill, and finish services for Phase I and II trials. Credit: PeopleImages.com – Yuri A / Shutterstock.com.

Aptar Pharma has announced the acquisition of Mod3 Pharma’s clinical trial materials manufacturing capabilities from SWK Holdings.

Mod3 Pharma was previously known as Enteris Biopharma.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

This acquisition is a strategic move aimed at strengthening Aptar Pharma’s support for the early-stage development of drugs by providing formulation, fill, and finish services for Phase I and II clinical trials, and promoting the adoption of its devices in early-stage clinical programmes.

It is said to build upon a previous partnership between the two companies, which focused on providing Phase I and II current good manufacturing practices (cGMP) fill and finish services for orally inhaled nasal drug products (OINDPs) to the customers of Aptar.

Mod3 Pharma CEO Dr Paul Shields said: “We are delighted to become part of the Aptar family. This acquisition reflects our shared commitment to accelerating the development of innovative therapies and bringing them to patients faster.”

Aptar Pharma’s expansion also aims to accelerate the adoption of new drug delivery technologies.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Initially focusing on OINDPs, there is potential for growth into other areas, such as ophthalmic, dermal, injectable, and secondary packaging solutions, using Aptar’s active material science solutions.

Aptar Pharma president Gael Touya said: “Our vision at Aptar Pharma is clear: from formulation to patient.

“By integrating Phase I and II clinical manufacturing capabilities, we’re not just expanding our technical footprint, we’re deepening our commitment to customers seeking a seamless and accelerated path to market.”

Following the acquisition, Aptar Pharma will operate a US Food and Drug Administration (FDA)-inspected facility in New Jersey, US.

The site is equipped with cGMP cleanrooms, fill-finish technologies, active pharmaceutical ingredient (API) suites, and biologics capabilities.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact